The Smoking Paradox: A Twist in the Tale of Vasospastic Angina

Matthew V. Tran¹, Eric Marceau²,³, Pei-Yu Lee⁴, Mark Chandy⁵,⁶,⁷, Ian Y. Chen²,³*

¹Department of Internal Medicine, Stanford University School of Medicine, Stanford, California, USA; ²Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California, USA; ³Cardiology Section, Medical Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA; ⁴Pharmacy Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA; ⁵Robarts Research Institute, Western University, London, Ontario, Canada; ⁶Department of Medicine, Western University, London, Ontario, Canada; ⁷Department of Physiology and Pharmacology, Western University, London, Ontario, Canada

ABSTRACT
Cigarette smoking is undoubtedly the single most important risk factor and trigger for vasospastic angina, a condition also known as Prinzmetal angina secondary to coronary artery vasospasm. Even decades before vasospastic angina was first described by Dr. Myron Prinzmetal and his colleagues in 1959, there had been suspected connections between smoking and coronary artery vasospasm in what was alluded to then as “tobacco angina.” The intimate relationship between smoking and vasospastic angina has since been extensively researched and validated through decades of epidemiological and clinical studies. The fact that smoking would aggravate vasospastic angina comes with very little surprise, as it has been shown to adversely impact many of the disease processes thought to underlie vasospastic angina, including autonomic dysfunction, endothelial dysfunction, smooth muscle hyperactivity, and genetic susceptibility. While avoidance of smoking is the first logical step in managing smokers with vasospastic angina, there have been reported cases of vasospastic angina paradoxically triggered by smoking cessation or relieved with smoking resumption or nicotine replacement therapy. Thus, there appears to be patient-specific factors that could significantly alter the close connection between smoking and vasospastic angina, warranting further mechanistic investigations. In this review, we will examine this complicated relationship between smoking and vasospastic angina from multiple perspectives (historical, mechanistic, and clinical) and call attention to the “smoking paradox,” which, with further elucidation, may provide additional insight into the complex mechanisms of vasospastic angina and potentially new strategies to treat medically refractory vasospastic angina, at least in selected individuals.

Keywords: Smoking; Vasospastic angina; Coronary artery vasospasm; Smoking paradox

INTRODUCTION
Vasospastic Angina (VSA), historically referred to as Prinzmetal or variant angina, is characterized by angina occurring mostly at rest due to Coronary Artery Vasospasm (CAV). Dr. Myron Prinzmetal first described this “variant form of angina pectoris” in 1959 as rest angina associated with transient ST segment elevation that responded to sublingual nitrates [1]. This syndrome was referred to as “variant” in contrast to Dr. William Heberden’s classical description of effort angina with ST segment changes. Dr. Prinzmetal’s team hypothesized that the variant type of angina likely resulted from “temporary occlusion of large diseased artery with a narrow lumen due to normal increase in tonus of vessel wall.” With the introduction of coronary angiography years later, Dr. Prinzmetal’s suspicion that variant angina is attributable to CAV would be confirmed, and thus, the term “vasospastic angina” has since evolved [2,3]. However, little is known that Dr. Eli Moschcowitz might have described the same condition about thirty years earlier, which he then called “tobacco angina pectoris” [4]. Even before his time,
Dr. Henri Huchard in 1899 had described a form of angina associated with tobacco as “angine spasmo-tabagique,” which he speculatively attributed to spams of the coronary arteries [5]. Thus, the intimate connection between tobacco smoking and VSA had long been known before Dr. Prinzmetal’s time. While smoking is undoubtedly the most well-known risk factor and trigger for VSA, there have been reports to suggest that smoking cessation could paradoxically trigger angina and resumption of smoking could provide relief. In this article, we will review the current evidence on this intimate and yet increasingly complicated relationship between smoking and VSA and highlight areas of further opportunities to advance the management of VSA.

LITERATURE REVIEW

Epidemiological importance of smoking in vasospastic angina

It has been reported that nearly 50% of patients presenting with acute coronary syndrome could have CAV confirmed by coronary angiography with provocative testing [6]. However, the actual prevalence of VSA has not been comprehensively studied and appears to depend on the populations being studied, with some reports suggesting about 20% in Caucasian patients [7] and about 40% in Japanese patients presenting with angina [8]. There is a male predominance to this condition, but significant sex-specific differences in cardiovascular outcomes have not been consistently observed [9,10]. Because of significant heterogeneity in the clinical presentations, with some patients being asymptomatic, VSA is underdiagnosed [11]. The typical risk factors for coronary artery disease such as diabetes [12] and hypertension [13] do not fully extend to VSA, and smoking remains the single most important acquired risk factor from numerous studies [14-17]. Other known triggers of VSA include emotional stress, cold, stimulants, magnesium deficiency, hyperventilation, alcohol, and medications such as parasympathomimetics, ergot alkaloids, and nonselective beta-blockers [18].

Diagnosis of vasospastic angina

VSA is a condition that results primarily from the abnormal vasoreactivity of the epicardial coronary arteries and is associated with a heterogeneous angiographic presentation of CAV, from diffuse to focal and involving one or more coronary arteries. The latest guidelines advocate for the standardized use of the following criteria for a definitive diagnosis of VSA.

- Nitrate-responsive angina (i.e., rest angina, marked diurnal variation in exercise tolerance, hyperventilation as a precipitation factor, or response to Calcium Channel Blockers (CCBs) but not beta-blockers)
- Transient ischemic electrocardiogram changes
- Documented CAV (i.e., >90% spontaneous or provoked constriction on coronary angiography (Figure 1) with concurrent angina and ischemic electrocardiographic changes) [3]

Mechanisms of vasospastic angina in relation to smoking

The disease mechanisms of VSA are multifaceted and could involve microvascular dysfunction as a co-existing condition, which has been well-reviewed elsewhere [21,22]. Here, we will focus our review on the most essential mechanisms relevant to smoking that mainly impact the epicardial coronary arteries, which constitute the main location of vasomotion abnormality in VSA.

Autonomic dysfunction and smoking in vasospastic angina

Autonomic dysfunction in both arms of the autonomic nervous system is known to contribute to VSA (Figure 2).
Endothelial dysfunction and smoking in vasospastic angina

Endothelial cells lining the epicardial coronary arteries contribute to the regulation of vessel caliber by sensing coronary flow and releasing factors (e.g., NO) to cause relaxation of the underlying VSMCs during FMD. Endothelial cells also release NO to favor vasodilation in response to various endogenous substances (acetylcholine, serotonin, histamine) or endothelin-1 to favor vasoconstriction by activating the underlying VSMCs. Thus, endothelial dysfunction of the epicardial arteries typically manifests as either reduced FMD or acetylcholine-induced vasoconstriction, the latter of which forms the basis of provocative testing for VSA [25]. Indeed, multiple studies have found FMD to be reduced in patients with VSA, more so in coronary segments exhibiting vasospasm than those without [34,35]. Other studies have shown that intracoronary acetylcholine leads to vasospasm only in patients with VSA but not in those without [24,25]. The endothelial dysfunction underlying CAV has been associated with NO deficiency [36], which is the reason for using nitrates (NO donors) to treat VSA.

Cigarette smoking can aggravate VSA by causing further endothelial dysfunction. Many preclinical studies have shown that both cigarette smoking and nicotine can cause oxidative stress to impair endothelial function and reduce NO bioavailability [37], and these results appear to extend to humans. Both acute and chronic cigarette smoking have been shown to cause endothelial dysfunction and reduced FMD in the brachial arteries [38,39] which can be ameliorated with vitamin C (an antioxidant), suggesting the essential role of oxidative stress in smoking-related endothelial dysfunction [40]. Chronic cigarette smoking has also been shown to cause endothelial dysfunction in the epicardial coronary arteries, manifesting as either reduced FMD [41] or vasoconstriction in response to acetylcholine [42]. The smoking-induced impairment is at least partly reversible, as smoking cessation has been shown to reduce coronary vasoconstriction during acetylcholine challenge in patients with recent myocardial infarction [43].

Smooth muscle hyperreactivity and smoking in vasospastic angina

There appears to be some racial differences in the angiographic presentation of VSA, such that Japanese patients tend to have more diffuse or multivessel vasospasm, whereas Caucasians tend to present with focal vasospasm [44]. In contrast to the diffuse form, the focal form of CAV cannot be explained by generalized endothelial dysfunction alone and likely involves hypercontraction of VSMCs, which can be inferred from intracoronary Optical Coherence Tomography (OCT) of patients with VSA (Figure 3).
It has been shown in a porcine model of CAV that only coronary segments treated with interleukin-1β, but not those untreated, show inducible hypercontraction with intracoronary serotonin and histamine [46]. A molecular study using the same animal model has further implicated the activation of both protein kinase C and Rho-kinase pathways to cause VSMC hyperreactivity in the treated segments [47]. The fact that endothelium-dependent vasodilating responses can be preserved at these segments in this animal model [48], as well as at the vasospastic sites of patients [49], further supports smooth muscle hyperreactivity as an important disease mechanism of VSA.

Smoking appears to have a moderate effect on smooth muscle hypercontraction, which can occur with either reduced sensitivity to vasodilators or increased sensitivity to vasoconstrictors. Although some earlier studies have suggested otherwise [50], a more recent study using increasing doses of sublingual nitroglycerin has found that cigarette smoking can reduce nitroglycerin-mediated endothelium-independent vasodilation in human brachial artery and thus VSMC sensitivity to NO [51]. This observation is consistent with a prior study showing that chronic cigarette smoking can cause a mildly impaired nitroglycerin-mediated endothelium-independent vasodilation in the epicardial coronary arteries, compared to much greater impairment on endothelium-dependent vasodilation in the same subjects [41]. Nicotine alone also has been shown to enhance both norepinephrine-mediated vasoconstriction in human skin [52] and the contractile response to endothelin-1 in rat coronaries [53]. Thus, cigarette smoking and nicotine have the ability to alter VSMCs’ sensitivity to multiple vasoactive substances to favor vasoconstriction, although its effect is likely overall smaller compared to its impact on the endothelium.

**Genetic influences of vasospastic angina in relation to smoking**

Significant progress has been made over the past two decades to unravel the genetics of VSA. One of the most well-known genetic variants associated with VSA is the T786C variant of the Nitric Oxide Synthase 3 (NOS3) gene, which has been shown in vitro to confer reduced Endothelial Nitric Oxide Synthase (eNOS) activity [15,54], thus affirming NO deficiency as a critical contributor to VSA. Worth noting are also the C242T variant of the p22phox gene (also known as cytochrome B-245 alpha chain gene; CYBA) in men and the C634G variant of the Interleukin 6 (IL6) gene in women [16]. The former variant is associated with reduced superoxide production [55] and thus a protective variant less seen in VSA patients. These variants implicate both oxidative stress and inflammation in VSA and reveal important sex-specific differences in genetic susceptibility to VSA. The Ala370Ser variant of the Rho GTPase Activating Protein 9 (ARHGAP9) gene is another interesting variant implicated in VSA, which in mouse models causes increased vascular infiltration of hematopoietic cells (inflammation) and endothelial dysfunction [56], suggesting that perturbation of the extravascular compartment can also contribute to VSA. Most recently, the Aldehyde Dehydrogenase 2 (ALDH2) genotype, ALDH2*2, that underlies alcohol flush syndrome in East Asians [57] was found to be associated with VSA, providing a rationale for the greater prevalence of VSA in East Asians than Caucasians [58]. Compared to the various genetic variants identified, smoking is by far the single most consistent risk factor for VSA [15,16].

Smoking also affects many of the disease pathways related to the VSA-associated genetic variants and can cause significant gene-environment interactions. For instance, smoking can cause oxidative stress in endothelial cells and lead to NO deficiency and potentially worsening of angina in patients already with one or more of the pathogenic variants of the NOS3, CYBA, or ALDH2 genes. This is possible because the products of CYBA (p22phox) and ALDH2 are involved in the generation of reactive oxygen species and the metabolism of toxic aldehydes from cigarette smoke, respectively. Smoking has also been shown to cause increased blood levels of inflammatory cytokines such as tumor necrosis factor-α, interleukin-1β, and interleukin-6 (IL-6), and can potentially worsen angina in patients with variants related to cytokines (IL-6) or their potential cell targets (ARHGAP9). In fact, inflammatory cytokines have been shown to cause increased reactive oxygen species and endothelial dysfunction in animal models of smoking-induced vasculopathy [59]. Thus, although smokers have varying tendencies to experience VSA, those with a severe course could very well have significant underlying genetic predispositions worth investigating [19].

**Paradoxical effects of smoking on vasospastic angina**

There is little dispute that smoking is a strong trigger and contributor of VSA, but some case reports have ironically...
suggested the possibility of developing VSA after smoking cessation. The first case report of this phenomenon described a middle-aged female chronic cigarette smoker who experienced VSA one week after stopping cigarette smoking, with subsequent angiogram confirming CAV and esophageal manometry revealing diffuse esophageal vasospasm [60]. It was deduced that nicotine likely exerted "acetylcholine antagonist effects" to protect her from concurrent VSA (Figure 4) and esophageal vasospasm, as acetylcholine is the main neurotransmitter of the parasympathetic nervous system innervating both the coronary artery and esophageal smooth muscle cells. The site of nicotine’s action was presumed to be on the postganglionic nerves, which contain nicotinic, rather than muscarinic, acetylcholine receptors. The patient’s angina was eventually controlled with CCBs alone.

Which can be affected by patient-specific factors (e.g., concurrent diffuse esophageal spasm, heart transplant, and genetic susceptibility). Further research into how these patient-specific factors interact with smoking may provide insight on more effective strategies to treat resistant cases of VSA.

**DISCUSSION**

**Treatments for vasospastic angina and implications for smokers**

The treatment of VSA starts with lifestyle modifications, which in concert with medical therapy, typically provide adequate symptomatic control. Only rarely would non-medical or surgical intervention be needed to address medically refractory VSA.

**Lifestyle modifications**

Smoking cessation is the single most important intervention in smokers with VSA because those who continue to smoke are more likely to experience angina than those who successfully quit [61]. Concurrent abstinence from alcohol is also essential in smokers with the ALDH2* genotype (or alcohol flush reaction), which has been associated with reduced metabolism of harmful aldehydes from both alcohol and cigarette smoke [57]. Other substances that are known to trigger VSA, such as cocaine, methamphetamine, and marijuana, should also be avoided [62].

**Medical management**

Some medications can precipitate VSA and should be first withdrawn if clinically feasible. Nonselective beta-blockers can exacerbate VSA by blocking β2-adrenoreceptor-mediated vasodilatation and leaving α1-adrenoreceptor-mediated vasoconstrictive effects unopposed. Sumatriptan, a serotonin receptor agonist, is contraindicated in patients with VSA due to its ability to directly provoke CAV. Aspirin, which inhibits prostacyclin synthesis, has been reported to exacerbate VSA at high doses and should be judiciously used if otherwise indicated in patients with VSA [63].

For drug treatments, CCBs are first-line agents, which work by suppressing the calcium influx needed for VSMC contraction. CCB therapy is associated with reduced myocardial infarction in patients with VSA, with the second-generation CCBs more effective at preventing acute coronary syndrome than the first-generation agents [64]. When angina cannot be completely controlled with a single agent, dual CCB therapy can be considered for additional relief [65]. Long-acting nitrates are also frequently prescribed early in the management of VSA for symptomatic control. These agents are metabolized to NO in vivo, which directly causes VSMC relaxation. When used concomitantly with CCBs, however, they do not provide additional mortality benefit [66]. Nitrate tolerance is a major limitation of chronic nitrate therapy, and the use of multiple nitrates (including nicorandil) may be associated with adverse outcomes [66].
Patients with refractory VSA despite being on a combination of CCBs and nitrates could be trialed on other less conventional agents. Statins can be effective at reducing VSA because of their pleiotropic effects, including enhancement of NO activity, reduction of VSMC hyperactivity, and attenuation of vascular inflammation [67]. Their long-term mortality benefits in patients with VSA, however, are subjects of ongoing debate that remain to be further elucidated [68,69]. The Rho-kinase inhibitor fasudil works by inhibiting Rho-kinase, an enzyme that normally reduces myosin phosphatase activity to promote vasoconstriction. It specifically targets the VSMC hyperactivity underlying VSA and can suppress inducible vasospasm in patients with VSA [70]. However, it is only available in an intravenous form, which limits its use in the outpatient population. Cilostazol is a phosphodiesterase-3 inhibitor that promotes VSMC relaxation by increasing intracellular cyclic adenosine monophosphate. When used in combination with a CCB, cilostazol has been shown to significantly reduce the incidence of angina [71]. Magnesium supplementation has also been shown to cause coronary vasodilation and prevent acetylcholine-induced CAV in patients with VSA [72].

In smokers who develop refractory VSA only after smoking cessation, the possibility of a “smoking paradox” should be recognized after ruling out all other potential causes of VSA. If a paradoxical case is deemed probable, Nicotine Replacement Therapy (NRT) could be considered for symptomatic relief with significantly less cardiovascular risks than smoking resumption [73]. Compared to placebo control and other smoking cessation medications such as varenicline and bupropion, NRT does not appear to increase the risk of serious cardiovascular events [74]. Compared to cigarettes, NRT is deemed safer because it contains less nicotine and is devoid of other cardiotoxic substances (e.g., carbon monoxide, oxidant gases, and polycyclic aromatic hydrocarbons) that can contribute to an increased risk of cardiovascular events [32].

In all medically refractory cases, strong genetic susceptibility to VSA should be suspected, and its characterization may point to specific disease pathways of CAV that can be potentially remedied with specific drug treatments [19]. Such form of genetics-based personalized medicine, although not in current practice, should be studied and encouraged more if validated.

Non-medical interventions

In medically refractory cases, percutaneous coronary intervention could be attempted if an obstructive lesion is thought to be the persistent trigger of localized vasospasm. Left stellate ganglion block could be considered for short-term relief, and if effective, followed by bilateral thoracoscopic sympathectomy for more sustaining effects [75]. In very rare cases, cardiac autotransplantation could also provide short-term relief, but its long-term efficacy is likely limited by autonomic reinnervation, a process that can vary significantly among patients [19].

CONCLUSION

Since the initial description of tobacco angina followed by Prinzmetal angina and then VSA, there has been significant strides made to elucidate the intimate relationship between smoking and VSA. As the single most important risk factor for VSA, smoking contributes to many pathological processes underlying VSA (e.g., autonomic dysfunction, endothelial dysfunction, smooth muscle hyperreactivity) and can expose those patients with strong genetic predispositions. While generally considered harmful, smoking and nicotine could have rare paradoxical effects on certain individuals, raising the possibility that there are yet unfamiliar patient-specific factors that may influence patients’ vasoactive responses to smoking and nicotine. Although NRT could provide symptomatic relief as a safer alternative to smoking for these individuals, further research into the mechanisms underpinning this “smoking paradox” of VSA could potentially open the door for the development of more novel therapeutics for these individuals and those with medically refractory VSA.

ACKNOWLEDGMENT

We thank Dr. David Liang of Stanford University School of Medicine for kindly providing some of the angiographic images included in this article.

SOURCES OF FUNDING

This work was supported in part by the AHA 18CDA34110047 (IYC).

CONFLICT OF INTEREST

There are no conflicts of interest.

REFERENCES


